With improved management options for PD, patients are living longer and, as a result, more are suffering from long-term complications of disease and therapy. Although the influx of new medications has changed the landscape of pharmacologic options for PD patients, a reexamination of the older medications such as amantadine can offer evident benefit.
Amantadine retains its primary utility as a mild antiparkinsonian agent to be used mostly as adjunctive therapy, and occasionally in early monotherapy as a means to avoid early use of levodopa. Most recently, it is frequently being utilized as the only available antiparkinsonian agent to diminish dyskinesia and offer improvement of the PD symptoms simultaneously (71).
Was this article helpful?